Loading stock data…
SIBN
$15.53+0.56 (+3.74%)
Market ClosedLast close Jun 9
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SI-BONE, Inc. in the Healthcare sector is trading at $15.53. Wall Street consensus targets $24.12 (8 analysts), implying a +55.3% move over the next 12 months. The stock is currently 29% below its 52-week high of $21.89, remaining 1.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +55.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$15.53
Potential Downside
0%
Whystock Fair Value$15.53
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented tita...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.33%
Volume
Today's trading volume
322,824
Recent News
Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now
Si-Bone (SIBN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 71.1% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%
The consensus price target hints at a 65.3% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Si-Bone Stock Soared by Almost 20% on Tuesday
It's off to a roaring start as far as the financial year is concerned.
SI-BONE Inc (SIBN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...
SI-BONE Inc (SIBN) reports impressive international revenue growth and raises full-year guidance, while navigating challenges and capitalizing on new opportunities.